BioSpace News Archive

Cytokinetics is discontinuing the Phase III COURAGE-ALS trial in amyotrophic lateral sclerosis after its candidate reldesemtiv failed a planned interim analysis, the company announced Friday.

BioNTech will pay Shanghai-based Duality Biologics $170 million upfront for rights to two of its topoisomerase-1 inhibitor-based antibody drug conjugates.

In a potential leap forward for sickle cell disease, Vertex moved closer to launching its one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.

Almost two years after its launch, eye-focused gene therapy start-up Vedere Bio II is closing its doors, company leaders announced through a LinkedIn post over the weekend.

Windtree Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided key business updates.

SWK Holdings Corporation, a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided a business update and announced its financial and operating results for the fourth quarter ended December 31, 2022.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, will release first quarter 2023 financial results on Wednesday, April 26, 2023, prior to the market open.

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) today announced that JCR has signed a Research Collaboration, Option and License Agreement with Alexion, AstraZeneca Rare Disease (“Alexion”) to develop an undisclosed initial therapeutic molecule that applies JCR’s proprietary J-Brain Cargo®, blood-brain barrier (“BBB”) penetration technology, for the treatment of a neurodegenerative disease.

PDS Biotechnology Corporation announced its support for Oral, Head & Neck Cancer Awareness Month in April and Oral, Head & Neck Cancer Awareness Week, April 16-22, both of which are organized by the Head & Neck Cancer Alliance.

NewAmsterdam Pharma Company N.V., a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, announced the appointment of Janneke van der Kamp as an independent director to its Board of Directors.